INmune Bio, Inc. (INMB) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals several negative factors: a delay in the XPro FDA meeting, limited efficacy in the INKmune trial, and cautious partnership progress. While financial losses decreased and cash runway extends to Q4 2026, the need for additional financing looms. The Q&A session highlights uncertainties and management's reluctance to provide detailed guidance. These elements, combined with the lack of a new partnership announcement or strong guidance, suggest a negative stock price movement in the short term.
Key Financial Performance
Net loss attributable to common stockholders Approximately $6.5 million for the quarter ended September 30, 2025, compared with approximately $12.1 million for the comparable period in 2024. This represents a significant reduction in net loss year-over-year, attributed to decreased research and development expenses.
Research and development expenses Approximately $4.9 million for the quarter ended September 30, 2025, compared with approximately $10.1 million for the comparable period in 2024. This represents a reduction in R&D expenses year-over-year, likely due to the completion of certain clinical trials.
General and administrative expenses Approximately $2.5 million for the quarter ended September 30, 2025, compared with approximately $2.2 million for the comparable period in 2024. This represents a slight increase in G&A expenses year-over-year, potentially due to increased operational activities.
Cash and cash equivalents Approximately $27.7 million as of September 30, 2025. The company believes this is sufficient to fund operations into Q4 2026.
Shares of common stock outstanding Approximately 26.6 million shares as of October 30, 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
CORDStrom: Preparing for submission for marketing approval in the U.K. and U.S. Demonstrated benefits for patients with recessive dystrophic epidermolysis bullosa (RDEB), including reduced itch and improved quality of life. Potential for systemic treatment and platform expansion to other diseases, including cancer.
XPro: Submitted Phase II MINDFuL trial results for peer-review publication. Positive results in patients with higher baseline inflammation in Alzheimer's disease. Pursuing accelerated regulatory pathway and preparing for end of Phase II meeting with the FDA.
INKmune: Completed Phase II trial in prostate cancer ahead of schedule. Met primary endpoint and two secondary endpoints. Planning a randomized Phase II trial in 2026.
Financial Performance: Net loss reduced to $6.5 million in Q3 2025 from $12.1 million in Q3 2024. Cash and cash equivalents of $27.7 million, sufficient to fund operations into Q4 2026.
Strategic Focus: Transitioned focus from Alzheimer's trial to advancing platform drug programs. Developing three distinct drug platforms in parallel to strengthen opportunities.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approval Challenges: The company is preparing for regulatory submissions for CORDStrom in the U.K. and U.S., which involves complex data analysis and compliance with stringent manufacturing and testing standards. Failures in these areas could delay approvals.
Manufacturing and Testing Risks: The company faces challenges in confirming the mechanisms of action for CORDStrom and validating assays for drug potency, which are critical for regulatory approval. Failures in these processes have historically delayed other drug approvals.
Strategic Execution Risks: The company is managing three different drug platforms simultaneously, which could strain resources and impact the timely advancement of each program.
Alzheimer's Drug Development Challenges: XPro faces inherent challenges in Alzheimer's drug development, including the need for targeted patient selection and demonstrating disease-modifying effects. Regulatory alignment and securing an accelerated approval pathway are critical hurdles.
Financial Risks: The company reported a net loss of $6.5 million for the quarter and has cash reserves sufficient only until Q4 2026, which may limit its ability to fund operations and clinical trials beyond this period without additional financing.
Clinical Trial Risks: The INKmune program in prostate cancer showed limited efficacy in patients with high disease burden, raising concerns about patient selection and trial design for future studies.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
CORDStrom Program: The company is preparing for submission for marketing approval to regulatory bodies in the U.K. and the U.S. for CORDStrom, targeting mid-2026 for the U.K. marketing authorization application (MAA) and a few months later for the U.S. biologics licensing application (BLA). The drug has shown potential as a systemic treatment for recessive dystrophic epidermolysis bullosa (RDEB) and may be expanded to other indications in the future.
XPro Platform: The company is pursuing an accelerated regulatory pathway for XPro and preparing for an end of Phase II meeting with the FDA. They expect to receive feedback on the accelerated pathway and meeting minutes in Q1 2026. The drug has shown promise in treating neuroinflammation in Alzheimer's disease, particularly in patients with higher baseline inflammation, and has demonstrated no ARIA-related safety signals.
INKmune Program: The Phase II trial for INKmune in prostate cancer has been completed ahead of schedule, meeting the primary endpoint and two of three secondary endpoints. The company plans to design a randomized Phase II trial during 2026 as resources become available.
Financial Outlook: The company has cash and cash equivalents of approximately $27.7 million as of September 30, 2025, which is expected to fund operations into Q4 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the biggest questions or discussion topics for the end of Phase II meeting with the FDA regarding XPro?
A:The key questions include understanding the agency's view on EMACC, enrichment biomarkers for patients with greater inflammation, and the safety database requirements for moving into a registration trial.
Q:Why was there a delay in the end of Phase II meeting with the FDA for XPro?
A:The delay occurred because the company was unable to gather enough data in time to submit to the FDA for a Q4 meeting. They are being conservative and now expect the meeting to occur in Q1.
Q:How are partnership conversations for XPro progressing?
A:Partnership discussions are at a top-level stage, with potential partners waiting for regulatory feedback and more dataset information, including imaging data. The company aims to deliver a complete package before engaging in serious discussions.
Q:What is the future plan for the INKmune asset?
A:The company plans to gather more Phase II data in randomized trials for prostate and other diseases. They are open to partnership opportunities or potentially keeping the asset in-house depending on funding.
Q:Has there been any feedback from European regulators regarding a potential MAA filing for CORDStrom?
A:The company is preparing for a scientific advice meeting with the MHRA, expected early next year. They plan to submit the MAA to the MHRA by Q2 next year and believe this will positively influence the FDA's opinion.
Q:How does CORDStrom compare to gene therapies for RDEB?
A:CORDStrom offers a systemic solution, unlike topical gene therapies. It addresses systemic cytokines and inflammatory responses, potentially complementing gene therapies by addressing issues like itch, which is a major side effect of gene therapies.
Q:What makes CORDStrom unique compared to other MSC therapies?
A:CORDStrom uses MSCs from four pooled donors, selected for specific potencies tailored to disease mechanisms. This platform approach allows for targeted treatments for various diseases, making it distinct from other MSC therapies.
Q:What is the current treatment paradigm for RDEB in the U.K., and how might CORDStrom fit in?
A:Currently, there is no RDEB-specific treatment reimbursed by the NHS in the U.K. CORDStrom could fill this gap by offering a systemic and cost-effective solution, with strong demand from clinicians and patients.
Q:What data supports the systemic effect of CORDStrom?
A:Published trial data show systemic effects, including reduced itch and improved quality of life. Anecdotal evidence from patients and clinicians also supports these findings.
Q:What is the company's cash runway and key milestones?
A:The cash runway extends to Q4 next year. Key milestones include the end of Phase II meeting for XPro in Q1, MAA submission for CORDStrom by mid-next year, and additional data from the MissionEB program by the end of this year.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details about the type of questions for the FDA meeting, stating they were not ready to publicly disclose them. Additionally, they did not provide detailed data on the systemic effects of CORDStrom, citing ongoing independent analysis.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEO Secretary
CGMP
Division Maxim
Ellspermann
Group LLC
II MINDFuL
II trial
INKmune patient
INmune Bio
MINDFuL trial
Maxim Group
Phase II
Raymond Ltd
Research Division
Secretary Director
XPro alignment
activity
child itch
cycle
development milestone
disease modification
end Phase
evidence
finding
improvement
indication
indicator
insight
itch scratch
manuscript
matter
modification future
period
scratch wound
skin wound
stage development
trial INKmune
INMB Transcript
INmune Bio Inc. (INMB) Q1 2026 Earnings Call Prepared Remarks Transcript
Unknown5-8
The earnings call lacked critical information on financial performance, strategic initiatives, and operational updates. The focus on risks and uncertainties without providing clear guidance or positive developments contributes to a negative outlook. The absence of any positive shareholder return plans further weakens sentiment.
INmune Bio Inc. (INMB) Q4 2025 Earnings Call Transcript
Unknown3-30
The earnings call reveals several negative factors: XPro's Phase II trial failure, financial losses, and reliance on future funding. Despite potential in CORDStrom's expansion and sufficient cash reserves, regulatory risks and manufacturing challenges persist. The Q&A section did not alleviate concerns, and recent stock offerings could dilute value. These outweigh the positives, suggesting a negative stock price movement.
Coveo Solutions Inc. (CVO:CA) Q2 2026 Earnings Call Transcript
Unknown10-30
The earnings call presents a mixed sentiment. Positive aspects include strong generative AI revenue growth and successful commerce bookings. However, the renegotiated Salesforce contract and negative cash flow are concerns. The Q&A reveals some uncertainties, such as delayed deals and the impact of the Salesforce contract on guidance. Overall, these factors balance each other, leading to a neutral sentiment. Without market cap data, the stock's reaction is uncertain, but the mixed signals suggest limited short-term movement.
INmune Bio, Inc. (INMB) Q3 2025 Earnings Call Transcript
Unknown10-30
The earnings call reveals several negative factors: a delay in the XPro FDA meeting, limited efficacy in the INKmune trial, and cautious partnership progress. While financial losses decreased and cash runway extends to Q4 2026, the need for additional financing looms. The Q&A session highlights uncertainties and management's reluctance to provide detailed guidance. These elements, combined with the lack of a new partnership announcement or strong guidance, suggest a negative stock price movement in the short term.
INMB Slides
INMB Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
